Nathan Mohar (Wallrath Lab) publishes a first author paper titled "A genetics variant in SMAD7 acts as a modifier of LMNA-associated muscular dystrophy, implicating SMAD signaling as a therapeutic target" in

Science Advances [Mohar et al., 11 (16) eads7903 (2025)]